

**Purpose**

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

**Product**

Fund Name: **Biotechnology Fund**

Share Class Name: **Class I GBP Distribution Shares**

Manufacturer Name: **Polar Capital LLP**

ISIN: **IE00B42P0H75**

Website: **www.polarcapital.co.uk**

Call **+44 (0) 20 7227 2700** for more information.

The product is manufactured by Polar Capital LLP (the "Investment Manager"), authorised and regulated in the UK by the Financial Conduct Authority. The product is managed by Bridge Fund Management Limited (the "Manager"), authorised in Ireland and regulated by the Central Bank of Ireland ("CBI"). The CBI is responsible for supervising the Manager in relation to this Key Information Document.

**This Key Information Document is accurate as at 29 September 2023. Production date: 31 December 2023.**

**What is this product?****Type**

The Biotechnology Fund (the "Fund") is an investment fund. The Fund is a sub-fund of Polar Capital Funds plc (the "Company"), an umbrella type open-ended investment company with variable capital and segregated liability between funds, incorporated with limited liability under the laws of Ireland. This is an Undertaking for the Collective Investment in Transferable Securities (UCITS) product.

**Objectives**

The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.

**Investment Policy**

The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (GBP) benchmark as a performance target and to calculate the performance fee. The currency of the Fund is US Dollar and the currency of this share class is British Pounds (GBP).

Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors.

**Sustainable Finance Disclosure Regulation**

This Fund promotes environmental and/or social characteristics and is classified as an Article 8 fund under the EU's Sustainable

Finance Disclosure Regulation ("SFDR"). For more information please see the Fund's prospectus or by visiting [www.polarcapital.co.uk](http://www.polarcapital.co.uk).

**Intended Retail Investor**

This product is intended for all investors (including those with a basic level of investment knowledge) who are seeking a return on their investment and who can accept the risk of losing some or all of their original investment. The product should be considered a medium to long-term investment, defined as three years or more. This product is suitable for investors seeking an investment with sustainable characteristics.

**Term**

This product does not have a maturity date.

**Additional Information**

The product's administrator is Northern Trust International Fund Administration Services (Ireland) Limited and the depositary is Northern Trust Fiduciary Services (Ireland) Limited, both of Georges Court, 54-62 Townsend Street, Dublin, Ireland D02 R156. Further information and corporate documentation including the latest and historic Annual and Interim Reports, can be obtained in English from the website: [www.polarcapital.co.uk](http://www.polarcapital.co.uk). Please speak to your financial adviser for further information.

Share prices will be published on [www.polarcapital.co.uk](http://www.polarcapital.co.uk) on each valuation day. Please refer to the Company's prospectus for information on buying, switching and selling shares in the Fund. Shares can be bought and sold on days where banks are normally open for business in the United Kingdom and Ireland.

## What are the risks and what could I get in return?

### Risk Indicator



Lower Risk

Higher Risk

1	2	3	4	5	6	7
---	---	---	---	---	---	---

The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of the PRIIPs manufacturer to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

**If the product currency differs from your investment currency, the following applies: Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

Due to effects of unusual market conditions, other risks could be triggered. Please see below for more detail.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

Additional risks not included in the Risk Indicator above include: Concentration Risk, Investment Risk, Derivatives Risk, Currency Risk. Please refer to the Fund's Prospectus for all risks associated with investing in the Fund. The Fund is subject to tax laws and regulations of Ireland. Depending on your home country of residence, this might have an impact on your investment. Please speak to your financial adviser for further information.

### Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower. In particular, the figures quoted for the favourable performance, while based on actual performance, relate to performance during a period of exceptional circumstances that are not likely to be repeated. Markets could develop very differently in the future and past performance is not a guarantee or a reliable guide to future performance. The value of your investment may go down as well as up, and may vary.

Recommended holding period: 5 years Example Investment: GBP 10,000.		If you exit after 1 year	If you exit after 5 years
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
Stress	What you might get back after costs	1,410 GBP	1,120 GBP
	Average return each year	-85.87 %	-35.40 %
Unfavourable	What you might get back after costs	7,910 GBP	8,810 GBP
	Average return each year	-20.94 %	-2.50 %
Moderate	What you might get back after costs	11,170 GBP	19,280 GBP
	Average return each year	11.72 %	14.04 %
Favourable	What you might get back after costs	16,310 GBP	29,260 GBP
	Average return each year	63.09 %	23.95 %

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment between August 2021 and September 2023.

The moderate scenario occurred for an investment between December 2014 and December 2019.

The favourable scenario occurred for an investment in the benchmark between September 2013 and September 2018.

## What happens if Polar Capital LLP is unable to pay out?

Losses are not covered by an investor compensation or guarantee scheme. If Polar Capital LLP defaults, investors in the Fund would not face financial losses. The depositary is responsible for keeping the Fund's assets safe and separate from other funds. In the event of bankruptcy or insolvency of the depositary, investors may experience delays in transfers, subscriptions or redemptions and there is a risk of default.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- GBP 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	683 GBP	2,942 GBP
Annual cost impact (*)	6.8%	3.3% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 17.3% before costs and 14.0% after costs.

Figures may not sum due to rounding

## Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0.00% There is no entry fee for this product, however the product may charge an entry fee of up to 5% in the future.	Up to 500 GBP
Exit costs	0.00% There is no exit fee for this product.	0 GBP
Ongoing costs [taken each year]		
Management fees and other administrative or operating costs	1.12% of the value of your investment per year	112 GBP
Transaction costs	0.02% of the value of your investment per year. This is an estimate of costs incurred when we buy and sell underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	2 GBP
Incidental costs taken under specific conditions		
Performance fees	10.00% a year of any returns the Fund achieves above the benchmark for these fees.	70 GBP

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

Investment in this Fund may be appropriate for investors who plan to invest over the medium to long term (3 to 5 years). The recommended holding period is shown for illustrative purposes only. There are no penalties if you wish to redeem your investment prior to the recommended holding period. The Shares can be sold by ordinary investors using an intermediary (e.g. a stockbroker) when the markets on which they trade are open. An intermediary is likely to apply a commission to purchases and sales. The above mentioned period has been defined in accordance to the product characteristics.

## How can I complain?

If you have a complaint about the product, this document or the conduct of the manufacturer, please contact Polar Capital's investor relations team via email: [Investor-Relations@polarcapital.co.uk](mailto:Investor-Relations@polarcapital.co.uk) or call +44 (0) 207 227 2700. Alternatively, you can also write to Polar Capital, 16 Palace Street, London SW1E 5JD, United Kingdom.

## Other relevant information

The current performance scenarios and past performance of the Fund can be found by visiting [www.polarcapital.co.uk](http://www.polarcapital.co.uk)

The paying and representative agent in Switzerland is BNP PARIBAS, Paris, Zurich branch, Selnaustrasse 16, 8002 Zürich, Switzerland. The Prospectus, the Key Information Documents (KIDs), the Articles of Association and the annual and semi-annual reports can be obtained free of charge from the representative agent in Switzerland.